Sex Steroids Balance for Metabolic and Reproductive Health in Klinefelter Syndrome
Status:
Not yet recruiting
Trial end date:
2026-03-01
Target enrollment:
Participant gender:
Summary
The study seeks primarily to determine whether modulation of systemic and testicular sex
steroids balance by aromatase inhibitors will positively affect the metabolic health and
spermatogenesis of men with Klinefelter syndrome (KFS) as compared to the current state of
the art for each issue.
Secondary objectives of this study are (i) to unravel the heterogeneity of the reproductive
and metabolic phenotype of men with KFS by performing a multi-omic analysis in a large cohort
at baseline; (ii) to evaluate the efficacy of semaglutide-induced weight loss to achieve
metabolic and reproductive benefit in men with Klinefelter syndrome as compared to standard
testosterone replacement; (ii) to assess whether addition of hCG to aromatase inhibitors
further increases intratesticular testosterone and promotes spermatogenesis in men with KFS.